Mohit Narang
Experienced in Endometrial Cancer

Dr. Mohit Narang

Hematology Oncology | Oncology
Johns Hopkins Medicine
Maryland Oncology Hematology
10710 Charter Drive, Suite G020, Suite G020, 
Columbia, MD 
Offers Telehealth

Experienced in Endometrial Cancer
Johns Hopkins Medicine
Maryland Oncology Hematology
10710 Charter Drive, Suite G020, Suite G020, 
Columbia, MD 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

As an active participant in the medical community, Mohit Narang, M.D. has served as a primary investigator and research assistant on many trials. During Dr. Narang’s fellowship, he was honored with the invitation to attend the Masterclass in Clinical Oncology at Montecatini, Italy by the European School of Oncology. He holds professional memberships with the American Society of Clinical Oncology, American Society of Hematology, as well as the European Society of Medical Oncology. Learn more at marylandoncology.com.

Dr. Narang is rated as an Experienced provider by MediFind in the treatment of Endometrial Cancer. His top areas of expertise are Multiple Myeloma, Agranulocytosis, Paget Disease of the Breast, Thrombocytopenia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 28 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Christ Hospital, Internal Medicine, 2000
Specialties
Hematology Oncology
Oncology
Licenses
Specialist in AR
Board Certifications
American Board Of Internal Medicine
Fellowships
MSU College of Human Medicine, 2003
Hospital Affiliations
Johns Hopkins Howard County Medical Center
Languages Spoken
English
Gujarati 
Hindi
Urdu
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Johns Hopkins Healthcare
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE-MEDICAID PLAN
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Maryland Oncology Hematology
10710 Charter Drive, Suite G020, Suite G020, Columbia, MD 21044
Call: 410-964-2212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


5 Clinical Trials

A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor for Patients With Newly Diagnosed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Dexamethasone Oral, Daratumumab, Lenalidomide
Study Phase: Phase 2
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 31, 2024
Intervention Type: Drug, Device
Study Drugs: Gemcitabine, Nab-paclitaxel
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With NSCLC as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: April 30, 2024
Intervention Type: Biological, Drug
Study Drugs: Tomivosertib, Pembrolizumab
Study Phase: Phase 2
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy (FORTE)
Enrollment Status: Terminated
Publish Date: March 15, 2024
Intervention Type: Drug
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
An Open Label, Multi-center Protocol for U.S. Patients Enrolled in a Study of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative, High Risk Early Breast Cancer
Enrollment Status: Completed
Publish Date: October 11, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

28 Total Publications

Iron deficiency anemia in patients with heavy menstrual bleeding: The patients' perspective from diagnosis to treatment.
Iron deficiency anemia in patients with heavy menstrual bleeding: The patients' perspective from diagnosis to treatment.
Journal: Women's health (London, England)
Published: February 27, 2025
View All 28 Publications
Similar Doctors
Stephanie Gaillard
Distinguished in Endometrial Cancer
Dr. Stephanie Gaillard
Oncology
Distinguished in Endometrial Cancer
Dr. Stephanie Gaillard
Oncology

Skip Viragh Outpatient Cancer Center

201 North Broadway Street, Viragh BLDG 10th FL, Viragh BLDG 10th FL, 
Baltimore, MD 
 (15.4 miles away)
410-955-8964
Languages Spoken:
English, French
See accepted insurances
Offers Telehealth

Stéphanie Gaillard is a medical oncologist who specializes in the treatment of gynecologic malignancies. She recently joined the faculty of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center and is their Director of Gynecologic Cancer Trials. Dr. Gaillard earned her medical degree and doctoral degree in cancer biology from Duke University. Following medical school, she underwent residency training in Internal Medicine and fellowship training in Medical Oncology at the Johns Hopkins School of Medicine. Dr. Gaillard’s research focuses on the development of clinical trials aimed at improving outcomes by incorporating promising new biologic, targeted, and immune therapies into standard treatment regimens. Her translational research program focuses on understanding the immune environment associated with gynecologic cancers and mechanisms of resistance to current therapies. Dr. Gaillard is rated as a Distinguished provider by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Cervical Cancer, Tissue Biopsy, and Salpingo-Oophorectomy.

Rebecca L. Stone
Distinguished in Endometrial Cancer
Dr. Rebecca L. Stone
Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Cancer
Dr. Rebecca L. Stone
Oncology | Obstetrics and Gynecology

Johns Hopkins Outpatient Center

Baltimore, MD 
 (15.4 miles away)
410-955-8240
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Rebecca Stone is an associate professor in the Johns Hopkins Medicine Department of Gynecology and Obstetrics. Her area of clinical expertise is gynecologic cancers, including cervical, uterine, vulvar and ovarian cancer, as well as gestational trophoblastic disease. Dr. Stone is a highly skilled surgeon with expertise in laparoscopic and robotic surgery for gynecologic tumors. She also serves as director of the Gynecology Enhanced Recovery after Surgery initiative, an innovative, multidisciplinary program that improves recovery and healing time after major abdominal surgery, as well as minimizes health care costs for patients. Dr. Stone received her undergraduate degree in biology from the University of Virginia. She earned her medical degree from the University of Virginia School of Medicine, where she subsequently completed her residency in obstetrics and gynecology. Dr. Stone performed a four-year gynecologic oncology fellowship at the University of Texas MD Anderson Cancer Center. She also earned a master’s degree in cancer biology from the University of Texas in 2010. Prior to joining Johns Hopkins, Dr. Stone was an assistant professor at the University of Arkansas for Medical Sciences, where she was one of five gynecologic oncologists serving the entire state. Dr. Stone is internationally recognized for her research pertaining to early diagnosis and treatment of ovarian cancer. She is widely published in the field of gynecologic oncology, with first-author papers in the New England Journal of Medicine and Lancet Oncology, as well as over 40 co-authored manuscripts in peer-reviewed medical journals. She was honored with an award for one of the most influential papers published in the field of obstetrics and gynecology in 2012 and with an Ovarian Cancer Research Fund Grant for “Unplugging Ovarian Cancer from the Power of Platelets.” Dr. Stone strongly believes in a multidisciplinary team approach to gynecologic cancer care. She seeks to provide women with the most advanced and personalized treatment plans while best preserving quality of life. She enjoys working with community providers so that patients are comforted by receiving care close to home. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of Endometrial Cancer. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Hysterectomy, and Oophorectomy.

Edward J. Tanner
Distinguished in Endometrial Cancer
Dr. Edward J. Tanner
Oncology | Obstetrics and Gynecology
Distinguished in Endometrial Cancer
Dr. Edward J. Tanner
Oncology | Obstetrics and Gynecology

Johns Hopkins Health Care & Surgery Center — Bethesda

Bethesda, MD 
 (20.8 miles away)
202-243-5295
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Tanner, M.D., is a professor of gynecologic oncology in the Johns Hopkins Medicine Department of Gynecology and Obstetrics and the medical director for women’s health in the Johns Hopkins National Capital Region. Dr. Tanner is an internationally recognized expert in gynecologic surgery and is known for his surgical skills, compassionate bedside manner, leadership and teaching abilities. Dr. Tanner’s clinical interests include surgical management of advanced gynecologic cancers, including radical debulking surgery for ovarian cancer, as well as minimally invasive surgery for early-stage female cancers. He is particularly focused on developing innovative techniques that reduce complications and speed recovery time. His research interests include sentinel lymph node mapping in endometrial and cervical cancers, exploring ways to reduce complications for patients having surgery for advanced ovarian cancer, robotic single-site surgery and identifying new treatments for patients with uterine sarcoma. He has authored more than 80 articles in peer-reviewed medical journals and has lectured nationally and internationally on sentinel lymph node techniques, uterine sarcoma and surgical innovations for gynecologic cancer. He is the chapter author of “Surgery for Endometrial Cancer” in Telinde’s Operative Gynecology, the definitive textbook for gynecologic surgery techniques in the United States. Dr. Tanner is a member of the NRG Corpus Committee, which develops clinical trials for uterine cancer on behalf of the National Cancer Institute. A Maryland native, Dr. Tanner received his medical degree from the University of Alabama at Birmingham before returning to Baltimore to complete his residency in gynecology and obstetrics at The Johns Hopkins Hospital. He completed a fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center, where he was among the first fellows to complete an extensive training program in robotic surgery for gynecologic cancers. Dr. Tanner has served as a faculty member at The Johns Hopkins Hospital as well as the Marcia Stenn Professor and chief of gynecologic oncology at Northwestern University in Chicago. Having served as the gynecologic oncology fellowship program director at both The Johns Hopkins Hospital and Northwestern Memorial Hospital, Dr. Tanner taught the next generation of gynecologic surgeons and health care leaders. Dr. Tanner is rated as a Distinguished provider by MediFind in the treatment of Endometrial Cancer. His top areas of expertise are Endometrial Stromal Sarcoma, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Hernia Surgery, and Oophorectomy.

VIEW MORE ENDOMETRIAL CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Narang's expertise for a condition
ConditionClose
  • Elite
  • Multiple Myeloma
    Dr. Narang is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Agranulocytosis
    Dr. Narang is
    Distinguished
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Paget Disease of the Breast
    Dr. Narang is
    Distinguished
    . Learn about Paget Disease of the Breast.
    See more Paget Disease of the Breast experts
  • Thrombocytopenia
    Dr. Narang is
    Distinguished
    . Learn about Thrombocytopenia.
    See more Thrombocytopenia experts
  • Advanced
  • Adult Immune Thrombocytopenia
    Dr. Narang is
    Advanced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Adult Soft Tissue Sarcoma
    Dr. Narang is
    Advanced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • Anemia
    Dr. Narang is
    Advanced
    . Learn about Anemia.
    See more Anemia experts
  • Bone Tumor
    Dr. Narang is
    Advanced
    . Learn about Bone Tumor.
    See more Bone Tumor experts
  • Breast Cancer
    Dr. Narang is
    Advanced
    . Learn about Breast Cancer.
    See more Breast Cancer experts
  • Choriocarcinoma
    Dr. Narang is
    Advanced
    . Learn about Choriocarcinoma.
    See more Choriocarcinoma experts
View All 39 Advanced Conditions
  • Experienced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Narang is
    Experienced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Narang is
    Experienced
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Narang is
    Experienced
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Acute Myelomonocytic Leukemia
    Dr. Narang is
    Experienced
    . Learn about Acute Myelomonocytic Leukemia.
    See more Acute Myelomonocytic Leukemia experts
  • ALK-Positive Non-Small Cell Lung Cancer
    Dr. Narang is
    Experienced
    . Learn about ALK-Positive Non-Small Cell Lung Cancer.
    See more ALK-Positive Non-Small Cell Lung Cancer experts
  • Alveolar Soft Part Sarcoma
    Dr. Narang is
    Experienced
    . Learn about Alveolar Soft Part Sarcoma.
    See more Alveolar Soft Part Sarcoma experts
View All 112 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.